Daiichi Sankyo/Ranbaxy deal is binding, companies stress
This article was originally published in Scrip
Apparently tiring of media and investor speculation about possible counter-bids and potential back-tracking, Daiichi Sankyoand Ranbaxyhave issued a statement stressing that their merger agreement is "binding and final", subject to requisite regulatory approvals. Both firms and Ranbaxy's controlling Singh family "remain committed to the transaction and…stand by the deal and confirm that the terms of the deal remain unchanged", the statement said. It added that the share transactions had been approved unanimously by both boards, and now also by shareholders, which "clears the decks for the deal to proceed as planned".
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.